NYSEAMERICAN:OCX - OncoCyte Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $2.85 -0.05 (-1.72 %) (As of 07/18/2018 02:53 AM ET)Previous Close$2.90Today's Range$2.70 - $2.9552-Week Range$1.10 - $7.64Volume57,400 shsAverage Volume83,337 shsMarket Capitalization$67.57 millionP/E RatioN/ADividend YieldN/ABetaN/A Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc. Receive OCX News and Ratings via Email Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical SymbolNYSEAMERICAN:OCX CUSIPN/A Webwww.oncocyte.com Phone+1-510-7750515 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on Equity-404.76% Return on Assets-209.93% Miscellaneous EmployeesN/A Outstanding Shares39,400,000Market Cap$67.57 OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions What is OncoCyte's stock symbol? OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX." How were OncoCyte's earnings last quarter? OncoCyte Corp (NYSEAMERICAN:OCX) issued its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.01. View OncoCyte's Earnings History. When is OncoCyte's next earnings date? OncoCyte is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for OncoCyte. What price target have analysts set for OCX? 2 brokers have issued 12-month target prices for OncoCyte's stock. Their predictions range from $7.00 to $7.00. On average, they anticipate OncoCyte's share price to reach $7.00 in the next year. This suggests a possible upside of 145.6% from the stock's current price. View Analyst Ratings for OncoCyte. What is the consensus analysts' recommendation for OncoCyte? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." Are investors shorting OncoCyte? OncoCyte saw a decline in short interest during the month of June. As of June 29th, there was short interest totalling 558,970 shares, a decline of 15.7% from the June 15th total of 663,123 shares. Based on an average daily trading volume, of 91,409 shares, the days-to-cover ratio is currently 6.1 days. Currently, 3.0% of the shares of the stock are short sold. View OncoCyte's Current Options Chain. Who are some of OncoCyte's key competitors? Some companies that are related to OncoCyte include ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV), Faron Pharmaceuticals Oy (FARN), Bionomics (BNO), Fennec Pharmaceuticals (FRX), ImmunoVaccine (IMMVF), Arix Bioscience (ARIX), Mereo BioPharma Group (MPH), Ampio Pharmaceuticals (AMPE), Immupharma (IMM), Verona Pharma (VRP), Emblem (EMC), Cannabics Pharmaceuticals (CNBX) and Oxford Biodynamics (OBD). Who are OncoCyte's key executives? OncoCyte's management team includes the folowing people: Mr. William Annett, Pres, CEO & Director (Age 64)Mr. Mitchell S. Levine, Chief Financial OfficerDr. Kristine C. Mechem Ph.D., VP of Marketing & PlanninngDr. Lyndal K. Hesterberg Ph.D., Sr. VP of R&DMr. Michael G. Vicari, VP of Sales Has OncoCyte been receiving favorable news coverage? Headlines about OCX stock have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm identifies negative and positive media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OncoCyte earned a media sentiment score of 0.07 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 45.68 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term. How do I buy shares of OncoCyte? Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is OncoCyte's stock price today? One share of OCX stock can currently be purchased for approximately $2.85. How big of a company is OncoCyte? OncoCyte has a market capitalization of $67.57 million. How can I contact OncoCyte? OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-7750515. MarketBeat Community Rating for OncoCyte (NYSEAMERICAN OCX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 89 (Vote Outperform)Underperform Votes: 79 (Vote Underperform)Total Votes: 168MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What does relative strength index mean?